Page last updated: 2024-11-09

(3-hydroxyphenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2204910
CHEMBL ID1326646
CHEBI ID123347
SCHEMBL ID17131913

Synonyms (17)

Synonym
MLS000050509 ,
3-[(4-benzyl-1-piperazinyl)carbonothioyl]phenol
smr000076439
CHEBI:123347
AKOS000351779
(4-benzylpiperazin-1-yl)-(3-hydroxyphenyl)methanethione
HMS2367E14
CHEMBL1326646
bdbm34428
cid_2204910
(4-benzylpiperazino)-(3-hydroxyphenyl)methanethione
(3-hydroxyphenyl)-[4-(phenylmethyl)piperazin-1-yl]methanethione
(3-hydroxyphenyl)-[4-(phenylmethyl)-1-piperazinyl]methanethione
Q27213056
SCHEMBL17131913
SR-01000275228-1
sr-01000275228
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency12.58930.141337.9142100.0000AID1490
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.22020.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency19.95260.28189.721235.4813AID2326
hemoglobin subunit betaHomo sapiens (human)Potency3.98110.31629.086131.6228AID925
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency14.12540.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID540317
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency15.00300.168316.404067.0158AID720504
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)EC50 (µMol)50.00000.00070.36512.8530AID854
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of cell population proliferationSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSphingosine 1-phosphate receptor 2Homo sapiens (human)
actin cytoskeleton organizationSphingosine 1-phosphate receptor 2Homo sapiens (human)
filopodium assemblySphingosine 1-phosphate receptor 2Homo sapiens (human)
excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of establishment of endothelial barrierSphingosine 1-phosphate receptor 2Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
integrin bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
postsynapseSphingosine 1-phosphate receptor 2Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]